

II. AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended): A method for the prevention of the loss of visual acuity associated with AMD, which comprises, ~~juxtapositionally~~ administering a pharmaceutically effective amount of the compound anecortave acetate or its corresponding alcohol, wherein said administering is by a method selected from the group consisting of posterior juxtapascleral injection, juxtapascleral implant, intravitreal injection, or implant.

Claim 2 (original): The method of claim 1, wherein the compound is administered as a juxtapascleral depot.

Claim 3 (original): The method of claim 2, wherein the depot comprises 3 mg – 30 mg of compound.

Claim 4 (original): The method of claim 3, wherein the depot comprises 15 mg of compound.

Claim 5 (currently amended): A method for maintaining visual acuity in a person suffering from AMD, which comprises ~~juxtapositionally~~ administering a pharmaceutically effective amount of the compound anecortave acetate or its corresponding alcohol, wherein said administering is by a method selected from the group consisting of posterior juxtapascleral injection, juxtapascleral implant, intravitreal injection, or implant.

Claim 6 (original): The method of claim 5, wherein the compound is administered as a juxtapascleral depot.

Serial No.: unknown

Filed: 26 June 2003

Page 3

Claim 7 (original): The method of claim 6, wherein the depot comprises 3 mg – 30 mg of compound.

Claim 8 (original): The method of claim 7, wherein the depot comprises 15 mg of compound.

Claim 9 (currently amended): A method for the inhibition of lesion growth associated with AMD, which comprises ~~juxtap sclerally~~ administering a pharmaceutically effective amount of the compound anecortave acetate or its corresponding alcohol, wherein said administering is by a method selected from the group consisting of posterior juxtap scleral injection, juxtap scleral implant, intravitreal injection, or implant.

Claim 10 (original): The method of claim 9, wherein the compound is administered as a juxtap scleral depot.

Claim 11 (original): The method of claim 10, wherein the depot comprises 3 mg – 30 mg of compound.

Claim 12 (original): The method of claim 11, wherein the depot comprises 15 mg of compound.

Claim 13 (currently amended): The method of ~~claim~~ any one of claims 1, 5, or 9, wherein the compound is administered in a juxtap scleral implant.

Claim 14 (original): The use of anecortave acetate or its corresponding alcohol for the preparation of a medicament for the prevention of the loss of visual acuity associated with AMD.

Claim 15 (original): The use of anecortave acetate or its corresponding alcohol for the preparation of a medicament for maintaining visual acuity in a person suffering from AMD.

Claim 16 (original): The use of anecortave acetate or its corresponding alcohol for the preparation of a medicament for the inhibition of lesion growth associated with AMD.

Claim 17 (original): The use according to Claims 14-16 wherein the preparation is administered as a juxtascleral depot.

Claim 18 (original): The use according to Claim 17 wherein the depot comprises 3 mg – 30 mg of anecortave acetate or its corresponding alcohol.

Claim 19 (original): The use according to Claim 18 wherein the depot comprises 15 mg of anecortave acetate or its corresponding alcohol.

Claim 20 (original): The use according to Claims 14 – 16 wherein the preparation is administered as a juxtascleral implant.

Claim 21 (new): A method for inhibiting blood vessel growth associated with AMD, said method comprising administering a pharmaceutically effective amount of the compound anecortave acetate or its accompanying alcohol, wherein the administering is by juxtascleral injection, intravitreal injection, juxtascleral implant, or other implant.

Claim 22 (new): The method of claim 21, wherein the amount of compound administered is from 3 mg to 30 mg.

Claim 23 (new): The method of claim 22, wherein the amount of compound administered is 15 mg.

Serial No.: unknown

Filed: 26 June 2003

Page 5

Claim 24 (new): The method of claim 9, wherein the lesion is a predominantly classic subfoveal lesion.

Claim 25 (new): The method of claim 9, wherein the lesion is a minimally classic lesion.